Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1701 in Relapsed/Refractory B-Cell Lymphomas
NCT07316920Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1701 in B cell lymphoma. Primary endpoints: Toxicity and adverse-event grading up to 12 months and Cytokine Release Syndrome grading up to 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
RN1701
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07316920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07316920.